Targets › KIT
52 programs from 40 companies in 298 trials: 178 Phase 2, 76 Phase 1, 39 Phase 3, 5 Phase 4; Oncology, Gastroenterology, Hematology; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. (UniProt, P10721)
Open in Phaseline: the race on KIT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | Catequentinib Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 4 | Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma … | Dec 2026 |
| Blueprint Medicines | Avapritinib (BLU-285) Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 4 | Mastocytosis, Systemic; Indolent Systemic Mastocytosis; AML (Acute Myelogenous Leukemia); Anatomic Stage IV Breast Cancer AJCC v8 … | Jun 2027 |
| Gossamer Bio USA | Seralutinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor | KIT, PDGFRB, PDGFRA, CSF1R | Phase 3 | Pulmonary Arterial Hypertension | Dec 2026 |
| Deciphera Pharmaceuticals | Vimseltinib (DCC-3014) KIT/PDGFRA/CSF1R inhibitor | CSF1R, KIT, PDGFRA | Phase 3 | Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants … | Dec 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| Xynomic Pharmaceuticals | Pazopanib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory … | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | AL2846 Capsule Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET | MET, KIT, FLT4, RET | Phase 3 | Thyroid Cancer | Jan 2027 |
| National Cancer Institute (NCI) | Pazopanib Hydrochloride Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid Neoplasm | Feb 2027 |
| Deciphera Pharmaceuticals | Ripretinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 3 | GIST; Gastrointestinal Stromal Tumors | Mar 2027 |
| Daiichi Sankyo | Pexidartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT | Phase 3 | Tenosynovial Giant Cell Tumor; Neurofibroma, Plexiform | Mar 2027 |
| Daiichi Sankyo | Quizartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT, PDGFRB, PDGFRA | Phase 3 | Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult … | May 2027 |
| Jiangsu HengRui Medicine | Famitinib Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | KIT, FLT1, FLT3, PDGFRB, PDGFRA | Phase 3 | Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm … | May 2027 |
| GSK | IDRX-42 (GSK6042981, velzatinib) Receptor tyrosine kinase inhibitor | KIT, PDGFRA | Phase 3 | Gastrointestinal Neoplasms; Gastrointestinal Stromal Neoplasms | Nov 2027 |
| Advenchen Laboratories | Catequentinib (AL3818) Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 3 | Alveolar Soft Part Sarcoma | Dec 2027 |
| AB Science | Masitinib Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FGFR3, KIT, PDGFRB, PDGFRA | Phase 3 | Amyotrophic Lateral Sclerosis | Dec 2027 |
| Alliance for Clinical Trials in Oncology | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 3 | Clear Cell Renal Cell Carcinoma | Nov 2037 |
| Roche | Sorafenib Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 3 | Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma … | – |
| Jiangxi Provincial Cancer Hospital | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT) | VEGFR, FGFR, RET, KIT | Phase 2 | Esophageal Squamous Cell Carcinoma | Nov 2026 |
| M.D. Anderson Cancer Center | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine Tumor | Dec 2026 |
| University of Utah | XL092 (Zanzalintinib) Multi-target kinase inhibitor targeting FGFR, VEGFR, and KIT | FGFR, VEGFR, KIT | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Sun Yat-sen University | Anlotinib Hydrochloride Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET | VEGFR, PDGFRA, PDGFRB, FLT1, KIT | Phase 2 | Glioblastoma | Dec 2026 |
| Blueprint Medicines | BLU-808 Wild type KIT inhibitor | KIT | Phase 2 | Chronic Inducible Urticaria | Dec 2026 |
| Canadian Cancer Trials Group | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Rare Tumours | Dec 2026 |
| University of Miami | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Dec 2026 |
| National Cancer Institute (NCI) | Imatinib Mesylate Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 2 | Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure Syndrome | Mar 2027 |
| National Cancer Institute (NCI) | Sorafenib Tosylate Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 2 | Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Sarcoma Alliance for Research through Collaboration | Bezuclastinib KIT inhibitor | KIT | Phase 2 | Gastrointestinal Stromal Tumors | Jun 2027 |
| Sarcoma Alliance for Research through Collaboration | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Jun 2027 |
| Fudan University | Sitravatinib Small molecule inhibitor of receptor tyrosine kinases | PDGFRA, KIT, RET, FLT3 | Phase 2 | Metastatic Breast Cancer | Jun 2027 |
| Cogent Biosciences | bezuclastinib KIT inhibitor | KIT | Phase 2 | Advanced Systemic Mastocytosis (AdvSM); SSM | Jul 2027 |
| American Society of Clinical Oncology | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Lymphoma, Non-Hodgkin | Dec 2027 |
| Bai-Rong Xia | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Ovary Cancer | Dec 2027 |
| Memorial Sloan Kettering Cancer Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Osteosarcoma | Mar 2028 |
| Bayer | Regorafenib (BAY73) Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor | ABL1, RAF1, KIT, FGFR1, MAPK11 | Phase 2 | Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic … | Apr 2028 |
| Eye & ENT Hospital of Fudan University | Anlotinib Hydrochloride Multi-target tyrosine kinase inhibitor | VEGFR, FGFR, RET, KIT | Phase 2 | Adenoid Cystic Carcinoma | Jun 2028 |
| National Cancer Institute (NCI) | Briquilimab Stem cell growth factor receptor inhibitor | KIT | Phase 2 | GATA2 | Jul 2028 |
| M.D. Anderson Cancer Center | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 2 | Renal Cell Carcinoma | Nov 2028 |
| Novartis | Midostaurin Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FLT3, KIT, PDGFRB, PDGFRA, PRKD3 | Phase 2 | FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid Leukemia | May 2029 |
| Blueprint Medicines | Elenestinib (BLU-263) KIT inhibitor | KIT | Phase 2 | Indolent Systemic Mastocytosis | Sep 2032 |
| Taiho Pharmaceutical | Imatinib Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 1 | Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic … | Dec 2026 |
| University of Florida | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Bile Duct Cancer | Dec 2026 |
| AstraZeneca | cediranib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | KIT, PDGFRB, PDGFRA, FLT1, FLT4 | Phase 1 | Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer … | Dec 2026 |
| National Heart, Lung, and Blood Institute (NHLBI) | briquilimab Stem cell growth factor receptor inhibitor | KIT | Phase 1 | Sickle Cell Anemia; Sickle Cell Disease | Jan 2027 |
| Etnova Therapeutics | ETN101 Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB | FLT3, KIT, VEGFR2, PDGFRB | Phase 1 | Hepatocellular Carcinoma | Mar 2027 |
| State University of New York at Buffalo | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Carcinoma, Renal Cell | Jul 2027 |
| University of Colorado, Denver | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Osteosarcoma | Aug 2027 |
| Novelty Nobility | NN3201 anti-c-Kit antibody-drug conjugate with MMAE payload | KIT | Phase 1 | Gastrointestinal Stromal Tumors | Aug 2027 |
| Porteus, Matthew, MD | Briquilimab (JSP191) Stem cell growth factor receptor inhibitor | KIT | Phase 1 | Fanconi Anemia | Dec 2027 |
| Rabin Medical Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Solid Tumors Refractory to Standard Therapy | Jan 2028 |
| Ono Pharmaceutical | Ripretinib (DCC-2618) Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 1 | Gastrointestinal Stromal Tumors | Feb 2028 |
| National Cancer Institute (NCI) | Tivozanib (AV-951) Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Cholangiocarcinoma | Dec 2028 |
Gastrointestinal Stromal Tumors (11) Hepatocellular Carcinoma (10) Acute Myeloid Leukemia (10) Colorectal Cancer (5) Soft Tissue Sarcoma (4) Cervical Cancer (4) Breast Cancer (4) Renal Cell Carcinoma (4) Metastatic Colorectal Cancer (3) Unresectable Hepatocellular Carcinoma (3) Non-Small Cell Lung Cancer (3) Osteosarcoma (3)
small molecule (38), mixed (11), antibody (2), other (1)
National Cancer Institute (NCI) (6) Blueprint Medicines (3) Chia Tai Tianqing Pharmaceutical Group (2) Deciphera Pharmaceuticals (2) Daiichi Sankyo (2) Sarcoma Alliance for Research through Collaboration (2) M.D. Anderson Cancer Center (2) Canadian Cancer Trials Group (1) Novartis (1) Exelixis (1) Ono Pharmaceutical (1) Alliance for Clinical Trials in Oncology (1) Bayer (1) Gossamer Bio USA (1) Fudan University (1) University of Florida (1) Etnova Therapeutics (1) Sun Yat-sen University (1) Memorial Sloan Kettering Cancer Center (1) Advenchen Laboratories (1)
PDGFRB (29) PDGFRA (25) FLT3 (19) CSF1R (17) FLT4 (8) FLT1 (7) KDR (6) FGFR1 (4) FGFR3 (4) RET (4) VEGFR (4) RAF1 (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.